Chromadex Corp (NASDAQ:CDXC) – Analysts at B. Riley dropped their Q3 2019 earnings per share (EPS) estimates for shares of Chromadex in a research note issued to investors on Thursday, August 8th. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings per share of ($0.12) for the quarter, down from their previous forecast of ($0.09). B. Riley also issued estimates for Chromadex’s Q4 2019 earnings at ($0.16) EPS, FY2019 earnings at ($0.56) EPS and FY2020 earnings at ($0.24) EPS.

Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $11.10 million during the quarter, compared to the consensus estimate of $10.81 million. Chromadex had a negative net margin of 85.86% and a negative return on equity of 136.15%.

Several other research firms have also issued reports on CDXC. HC Wainwright set a $7.00 price objective on Chromadex and gave the company a “buy” rating in a research note on Tuesday, May 28th. Zacks Investment Research upgraded Chromadex from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, BidaskClub lowered Chromadex from a “buy” rating to a “hold” rating in a research note on Friday, May 24th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Chromadex presently has a consensus rating of “Buy” and an average price target of $6.00.

NASDAQ:CDXC opened at $4.17 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.55 and a debt-to-equity ratio of 0.09. The company has a 50 day simple moving average of $4.45. The company has a market capitalization of $232.34 million, a price-to-earnings ratio of -6.84 and a beta of 1.27. Chromadex has a 12-month low of $2.79 and a 12-month high of $4.95.

Several hedge funds and other institutional investors have recently made changes to their positions in CDXC. BNP Paribas Arbitrage SA bought a new position in shares of Chromadex during the first quarter worth approximately $34,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Chromadex during the first quarter worth approximately $42,000. Spark Investment Management LLC acquired a new stake in Chromadex during the first quarter worth approximately $78,000. JPMorgan Chase & Co. grew its position in Chromadex by 377.2% during the second quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock worth $208,000 after buying an additional 35,418 shares in the last quarter. Finally, Miracle Mile Advisors LLC acquired a new stake in Chromadex during the first quarter worth approximately $272,000. Institutional investors own 18.05% of the company’s stock.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Read More: Dividend Aristocrat Index

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.